IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v42y2019i2d10.1007_s40264-018-0771-y.html
   My bibliography  Save this article

Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer

Author

Listed:
  • Danilo Rocco

    (Azienda Ospedaliera Dei Colli Monaldi)

  • Ciro Battiloro

    (Azienda Ospedaliera Dei Colli Monaldi)

  • Luigi Della Gravara

    (“Luigi Vanvitelli” University)

  • Cesare Gridelli

    (“S.G. Moscati” Hospital)

Abstract

The chimeric protein echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase, resulting from the rearrangement of the homonym genes, is one of the currently targetable oncogenic drivers in anaplastic lymphoma kinase-positive non-small-cell lung cancer. In fact, four first- and second-generation anaplastic lymphoma kinase tyrosine kinase inhibitors, crizotinib (PF-02341066), ceritinib (LDK378), alectinib (CH5424802), and brigatinib (AP26113), are presently approved for clinical practice; however, these agents are not devoid of complications and thus should be administered meaningfully. Furthermore, third-generation inhibitors are currently under development to overcome acquired resistance mechanisms inevitably resulting from treatment with first- and second-generation tyrosine kinase inhibitors. Therefore, this article aims to provide a comprehensive state-of-the-art review about the pharmacodynamics, pharmacokinetics, safety, and tolerability profiles of currently available and promising under-development anaplastic lymphoma kinase tyrosine kinase inhibitors.

Suggested Citation

  • Danilo Rocco & Ciro Battiloro & Luigi Della Gravara & Cesare Gridelli, 2019. "Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer," Drug Safety, Springer, vol. 42(2), pages 199-209, February.
    • Handle: RePEc:spr:drugsa:v:42:y:2019:i:2:d:10.1007_s40264-018-0771-y
    DOI: 10.1007/s40264-018-0771-y
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-018-0771-y
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-018-0771-y?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Rashmi R. Shah & Giuseppe Curigliano, 2019. "Safety of Novel Targeted Therapies in Oncology," Drug Safety, Springer, vol. 42(2), pages 157-158, February.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:42:y:2019:i:2:d:10.1007_s40264-018-0771-y. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.